NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

CompletedPhase 3

Sponsor: Pfizer

Conditions: Psoriatic Arthritis

Interventions: Tofacitinib, Placebo, Tofacitinib

Countries: China

This is a 6 month study investigating the effectiveness and safety of tofacitinib in treating signs and symptoms and improving physical function in Chinese patients with active psoriatic arthritis and had inadequate response to a conventional synthetic disease modifying anti-rheumatic drug. This is a China alone study.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Chinese patients
* Active arthritis at screening/baseline as indicated by \>/= 3 tender/painful and 3 swollen joints
* Active plaque psoriasis at screening
* Inadequate response to at least one conventional synthetic DMARD

Exclusion Criteria:

* Non-plaque forms of psoriasis (with exception of nail psoriasis)
* History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA

Locations (38)

Bengbu, Anhui, China
Hefei, Anhui, China
Hefei, Anhui, China
Beijing, Beijing Municipality, China
Beijing, Beijing Municipality, China
Chongqing, Chongqing Municipality, China
Xiamen, Fujian, China
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Shijiazhuang, Hebei, China
Harbin, Heilongjiang, China
Zhengzhou, Henan, China
Wuhan, Hubei, China
Changsha, Hunan, China
Changsha, Hunan, China
Zhuzhou, Hunan, China
Baotou, Inner Mongolia, China
Changzhou, Jiangsu, China
Nanjing, Jiangsu, China
Nanjing, Jiangsu, China
Nantong, Jiangsu, China
Suzhou, Jiangsu, China
Yangzhou, Jiangsu, China
Jiujiang, Jiangxi, China
Pingxiang, Jiangxi, China
Changchun, Jilin, China
Linyi, Shandong, China
Shanghai, Shanghai Municipality, China
Xi’an, Shanxi, China
+ 8 more on CT.gov